Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Scandinavian Journal of Gastroenterology
|
January 13, 2026
Prognostic value of <i>KRAS</i> gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
Saeed Aslani, Belinda Lee, Andrew H Strickland, et al.
Critical Reviews in Oncology/Hematology
|
October 26, 2002
Sentinel node biopsy: an in depth appraisal
Andrew H Strickland, Nicolas Beechey-Newman, Christopher B Steer, et al.
Cells
|
October 14, 2022
<i>KRAS</i> G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?
Henry Shen, Joanne Lundy, Andrew H Strickland, et al.
Asia-Pacific Journal of Clinical Oncology
|
December 1, 2010
A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas
Christos S Karapetis, Kerry A Cheong, Desmond Yip, et al.
Cancer Medicine
|
October 26, 2021
Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
Marianne S Elston, Amanda Love, Dev Kevat, et al.
Cancer Chemotherapy and Pharmacology
|
March 25, 2010
Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial
Peter Gibbs, Philip R Clingan, Vinod Ganju, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2025
The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
Michael Michael, Rachel Wong, Sanjeev Gill, et al.
Cancer Medicine
|
June 1, 2023
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results
Fortunato Ciardiello, Yung-Jue Bang, Andrés Cervantes, et al.
The Lancet. Oncology
|
December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial
Jong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
Marc Peeters, Timothy Jay Price, Andrés Cervantes, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Scandinavian Journal of Gastroenterology
|
January 13, 2026
Prognostic value of <i>KRAS</i> gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
Saeed Aslani, Belinda Lee, Andrew H Strickland, et al.
Critical Reviews in Oncology/Hematology
|
October 26, 2002
Sentinel node biopsy: an in depth appraisal
Andrew H Strickland, Nicolas Beechey-Newman, Christopher B Steer, et al.
Cells
|
October 14, 2022
<i>KRAS</i> G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?
Henry Shen, Joanne Lundy, Andrew H Strickland, et al.
Asia-Pacific Journal of Clinical Oncology
|
December 1, 2010
A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas
Christos S Karapetis, Kerry A Cheong, Desmond Yip, et al.
Cancer Medicine
|
October 26, 2021
Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
Marianne S Elston, Amanda Love, Dev Kevat, et al.
Cancer Chemotherapy and Pharmacology
|
March 25, 2010
Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial
Peter Gibbs, Philip R Clingan, Vinod Ganju, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2025
The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
Michael Michael, Rachel Wong, Sanjeev Gill, et al.
Cancer Medicine
|
June 1, 2023
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results
Fortunato Ciardiello, Yung-Jue Bang, Andrés Cervantes, et al.
The Lancet. Oncology
|
December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial
Jong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
Marc Peeters, Timothy Jay Price, Andrés Cervantes, et al.
Page
of 2